#### ACH2 Annual Scientific Conference

#### Abstract Instructions

Abstracts and oral presentations: Students and grant holders are encouraged to submit abstracts and to present their work. All submitted abstracts will be considered for oral presentation (time allocated to be confirmed).

**Abstract Submission:** Please save as a PDF with the following file name format: **2022 ACH2\_Surname** and email to Jo Reidy: [joanne.reidy@sydney.edu.au](mailto:joanne.reidy@sydney.edu.au) no later than **5:00pm AEST on Friday 6th May 2022.**

**Preparation of abstracts:** Please include the following sections: Authors, Addresses, Introduction, Methods, Results, Discussion and Conclusions. See example below. Calibri, 10 pt. throughout.

**Note:** Any specific abstract ordering of the program should be mentioned upon abstract submission (not after). The Committee will take this into consideration whilst preparing the layout of the program.

**Update from the Committee:**

This year we aim to have the event held onsite at The Canberra Rex Hotel for all attendees but if any COVID restrictions apply, we will opt for a portion in Canberra and Hubs in local states where an online component will be available. Our focus will remain on student presentations along with guest speakers focusing on career development.

We look forward to another rewarding ACH2 Annual Scientific Conference on **Wednesday 25 – Friday 27 May 2022**.

Please do not hesitate to contact [joanne.reidy@sydney.edu.au](mailto:joanne.reidy@sydney.edu.au) or a member of the organising committee should you have any questions or require any further information.

**Regards,**

**Organising Committee**

(Chaturaka Rodrigo [c.rodrigo@unsw.edu.au](mailto:c.rodrigo@unsw.edu.au), Purnima Bhat [purnima.bhat@anu.edu.au](mailto:purnima.bhat@anu.edu.au), Michael Roche [michael.roche@unimelb.edu.au](mailto:michael.roche@unimelb.edu.au), Anna Hearps [anna.hearps@burnet.edu.au](mailto:anna.hearps@burnet.edu.au) & Kirstie Bertram [kirstie.bertram@sydney.edu.au](mailto:kirstie.bertram@sydney.edu.au)).

Example abstract: 580 word maximum *(includes authors/affiliations)*

# **Conformational signalling in the gp120-gp41 envelope glycoprotein complex of HIV-1**

John Smith1,2, Mary Brown1,2, and Peter Green1,2,3

1Macfarlane Burnet Institute for Medical Research and Public Health, Prahran VIC 3004

2Department of Microbiology, Monash University

3Department of Microbiology and Immunology, The University of Melbourne

# **Introduction:** The gp120-gp41 glycoprotein complex of HIV-1 mediates viral entry. Interactions between gp120 and cellular receptors ……**…………..**

**Methods:** Cell-cell fusion was determined using a luciferase reporter assay where Env-293T effector cells were cocultured……………………..

**Results:** We found that the gp120-gp41 association function of the gp41 disulfide-bonded region was conserved……………………..

**Discussion:** Our data indicate that the conserved disulfide bonded region of gp41 mediates association with gp120………………….

**Conclusions:**

**Abstract Form**

|  |
| --- |
|  |

**Presenting Author:**

|  |  |
| --- | --- |
| Name: |  |
| Address of Institute: |  |
| Telephone: |  |
| Email: |  |

**Prize Eligibility**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Student | Research Assistant | Postdoc | Year PhD conferred: |  |

**Please indicate from 1 - 3 which categories your abstract belongs to.**

*(Please rank your selections with 1 being the most relevant)*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **HIV** | | **HCV/HBV** | | **Co-infection** | | **HTLV-1** | | **COVID-19 & BBV/STI** | |
|  | Genomics |  | Genomics |  | Genomics |  | Genomics |  | Genomics |
|  | Methods and Diagnostic Assays |  | Persistence and latency |  | Immunity |  | Immunity |  | Immunity |
|  | Microbicides |  | Replication |  | Pathogenesis |  | Pathogenesis |  | Pathogenesis |
|  | Persistence and latency |  | Therapies & Drug Resistance |  |  |  |  |  |  |
|  | Replication |  | Vaccines |  |  |  |  |  |  |
|  | Therapies and Drug Resistance |  | Virus & Host Cell Interactions |  |  |  |  |  |  |
|  | Vaccines |  |  |  |  |  |  |  |  |
|  | Virus and Host Cell Interactions |  |  |  |  |  |  |  |  |

**Additional Comments**

|  |
| --- |
|  |